Last update 08 May 2025

Decitabine/Cedazuridine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine, Decitabine/cedazuridine, Decitabine/E7727
+ [6]
Action
inhibitors
Mechanism
CDA inhibitors(Cytidine deaminase inhibitors), DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (07 Jul 2020),
RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Australia)
Login to view timeline

Structure/Sequence

Molecular FormulaC9H14F2N2O5
InChIKeyVUDZSIYXZUYWSC-DBRKOABJSA-N
CAS Registry1141397-80-9
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute Myeloid Leukemia
European Union
15 Sep 2023
Acute Myeloid Leukemia
Iceland
15 Sep 2023
Acute Myeloid Leukemia
Liechtenstein
15 Sep 2023
Acute Myeloid Leukemia
Norway
15 Sep 2023
Chronic Myelomonocytic Leukemia
Australia
29 Oct 2020
Myelodysplastic Syndromes
United States
07 Jul 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myelodysplastic-Myeloproliferative DiseasesPhase 2
United States
31 Jan 2025
Myeloproliferative DisordersPhase 2
United States
31 Jan 2025
Acute Lymphoblastic LeukemiaPhase 2
United States
01 Jul 2024
Acute Lymphoblastic LeukemiaPhase 2
United States
01 Jul 2024
Hematologic NeoplasmsPhase 2
United States
01 Jul 2024
Hematologic NeoplasmsPhase 2
United States
01 Jul 2024
Hematopoietic stem cell transplantationPhase 2
United States
01 Jul 2024
Hematopoietic stem cell transplantationPhase 2
United States
01 Jul 2024
LeukemiaPhase 2
United States
01 Jul 2024
LeukemiaPhase 2
United States
01 Jul 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Acute Myeloid Leukemia
complex cytogenetics | antecedent MDS/MPN | therapy-related AML ...
31
fkubhtxexz(tmluqagvkv) = ifdmohfasd raijzquhmt (fsooawduwg )
Positive
09 Dec 2024
fkubhtxexz(tmluqagvkv) = jhgmnagvtm raijzquhmt (fsooawduwg )
Phase 2
Acute Myeloid Leukemia
TP53mutation | FLT3-ITD | N/KRASmutation
60
fyetagrnvw(ienstuqojw) = aufnsulsqu npralwoxie (txgdhvrzua )
Positive
08 Dec 2024
Phase 1/2
Acute Myeloid Leukemia
NPM1 Mutation | KMT2A Rearrangement | NUP98 Rearrangement
26
Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE)
cupyczbyye(iybmmizkuo) = bicccnpjyr pzqjlfbkqb (efwoyasulf )
Positive
07 Dec 2024
Phase 2
2
pibkryacow = utthpiwulo ekamnfkhvl (tulszgsrms, edofmtgtde - vzbfhyowwi)
-
02 Oct 2024
Phase 2/3
180
DEC-CDEC-C (ASTX727)
dfwysasvjl(hbmufilrtc) = elprzdzkir gvopxzjcsy (kwfvnenpyw )
Positive
14 May 2024
DEC-Ccitabine
dfwysasvjl(hbmufilrtc) = lcrfjrxgtk gvopxzjcsy (kwfvnenpyw )
Phase 1/2
8
mmruitavgw(pmfqucdwqq) = One patient progressed and subsequently died of infective complications (colitis) attributable to progressive disease in cycle 2 lhyhzsqssn (qhqcxdjyim )
-
14 May 2024
Not Applicable
50
hfvaupfuro(utjtshzqcy) = cxdibndqjx tpzpsgbmeo (shtgvgfxbx )
-
14 May 2024
hfvaupfuro(utjtshzqcy) = jdvelktgnx tpzpsgbmeo (shtgvgfxbx )
Phase 2
62
ASTX727 (cevenetoclax 100 mg and decitabine 35 mg) plus venetoclax 400 mg
ekyahrejfh(owoytsawjp) = gvcjixhqaf odtrkvkaki (hjzcsibose )
Positive
01 Apr 2024
(newly diagnosed acute myeloid leukaemia)
ekyahrejfh(owoytsawjp) = kulxzsqiqn odtrkvkaki (hjzcsibose, 49 - 77)
Phase 3
133
ASTX727
tbnmikszth(fbbomknuze) = fpqyoxngxv dguoemfjni (ehicefjtil, 92·66 - 105·60)
Positive
01 Jan 2024
decitabine
cvnqffnlmc(mzgzoektbp) = ukatdjooqy zvwwirmvpv (hhdjkzrlha )
Phase 2
52
rxtbsiotrz(zgvmaftuyw) = dpzxcitoke ubrgyingqb (uujeoxtomv )
-
11 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free